Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. 3rd Annual Bone Marrow Transplant Winter Workshop December, 2015
2. 9th Annual Dutch Hematology Congress, Papendal, Arnhem, Netherlands January, 2015
3. Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL Cancers K. J. Curran, I. Riviere, R. Kobos, N.A. Kernan, MD1, F.Boulad, S.E. Prockop, A. Scaradavou, T.M. Renaud, N. Shukla, P.G Steinherz, J.H. Park, C. S. Sauter, R. J. O'Reilly, M. Sadelain, R.J. Brentjens American Society of Hematology (ASH) 56th Annual Meeting December, 2014
4. Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma C.S. Sauter, I.Riviere, Y. J. Bernal, X. Wang, T. J. Purdon, S. Yoo, C.H. Moskowitz, S. Giralt, M.J. Matasar, K.J. Curran, , J.H. Park, M. Sadelain, R.J. Brentjens American Society of Hematology (ASH) 56th Annual Meeting December, 2014
5. CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL Therapy J.H. Park, I. Riviere, X.Wang, Y.J Bernal,S. Yoo, T. Purdon, E.H Halton, H. Quintanilla, K J. Curran, C. S. Sauter, , M. L Davila, M. Sadelain, R.J. Brentjens American Society of Hematology (ASH) 56th Annual Meeting December, 2014
6. 4484 A Systemic Xenograft Model of Waldenström’s Macroglobulinemia Demonstrates the Potent Anti-Tumor Effect of Second Generation CD19 Directed Chimeric Antigen Receptor Modified T Cells in This Disease E.L Smith, Maria L. Palomba, J.H Park, R. J. Brentjens American Society of Hematology (ASH) 56th Annual Meeting December, 2014
7. Engineered T Cell Receptor-Mimic Antibody, (TCRm) Chimeric Antigen Receptor (CAR) T Cells Against the Intracellular Protein Wilms Tumor-1 (WT1) for Treatment of Hematologic and Solid Cancers S.Rafiq, Tao Dao, C. Liu, D.A. Scheinberg, R.J Brentjens American Society of Hematology (ASH) 56th Annual Meeting December, 2014
8. 20th Annual Meeting of Japan Society of Gene Therapy (JSGT) 2014, Tokyo, Japan August, 2014
9. Phase I Trial of Autologous CD19-targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL J. H. Park, I. Riviere, X. Wang, S.Bartido, M.Sadelain, R. J. Brentjens European Hematology Association (EHA) 19th Congress, June, 2014
10. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia R. Brentjens, M. Davila, I. Riviere, X. Wang, S. Bartido, J. Park, D. Bouhassira, K. Curran, S. Chung, J. Stefanski, O. Borquez-Ojeda, S. Giralt, M. Sadelain. merican Society of Gene and Cell Therapy (ASGCT) 17th Annual Meeting May, 2014
11. Tol2 Transposon System Mediates Stable Gene Transfer of CD19-Specific Chimeric Antigen Receptor To Primary Human T-Cells for the Treatment of B-Cell Malignancies T. Tsukahara, N. Iwase, C. Yamamoto, K.Ohmine, R. Uchibori, T. Teruya, H. Ido, M. Urabe, Hi. Mizukami, A. Kume, M. Nakamura, R. Brentjens, K. Kawakami, K. Ozawa merican Society of Gene and Cell Therapy (ASGCT) 17th Annual Meeting May, 2014
12. Graded potency of Chimeric Antigen Receptor (CAR)-engineered T cells for cancer Immunotherapy M. Sadelain, M. Condomines, Z. Zhao, R. J. Brentjens, I. Riviere. American Society of Clinical Oncology (ASCO) 48th Annual Meeting May, 2014
13. Blocking CD47 Improves CAR T Cell Therapy (Abstract# 770). American Society of Gene and Cell Therapy H J. Pegram, T J. Purdon, R J. Brentjens. merican Society of Gene and Cell Therapy (ASGCT) 17th Annual Meeting May, 2014
14. Roswell Park Cancer Institute Hematological Malignancies Conference 2014, May, 2014
15. Oncology Society of New Jersey Semi-Annual Meeting May, 2014
16. Phase I Trial of Autologous CD19-targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL J. H. Park, I. Riviere, X. Wang, S. Bartido, M. Sadelain, R. J. Brentjens American Society of Clinical Oncology (ASCO) 48th Annual Meeting May, 2014
17. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. M. Sadelain, R. Brentjens, M. Davila, I. Riviere, X. Wang, S. Bartido, J. Park, D. Bouhassira, K. Curran, S. Chung, J. Stefanski, O. Borquez-Ojeda, S. Giralt. American Association for Cancer Research (AACR) Annual Meeting April, 2014
18. GvH GvL 2014 Meeting, Thon-Dittmer Palais Regensburg, Germany March, 2014
19. EHA-SWG Scientific Meeting: Focus on New Molecular Insights in Emerging Therapeutic Strategies in Acute Lymphoblastic Leukemia (ALL), March, 2014
20. 18th Annual International Congress on Hematologic Malignancies, New York, NY February, 2014
21. Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related A. Kishtagari, I A Bowman, MD, M S Tallman, D. Douer, E. Berman, P G Maslak, R J Brentjens, E M Stein American Society of Hematology (ASH) 55th Annual Meeting December, 2013
22. Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL H Park, I. Rivière, X. Wang, J. Stefanski, Q. He, O. Borquez-Ojeda, T. Wasielewska, C. Taylor, J. Qu, S. Bartido, YJ Bernal, M. Sadelain, R J Brentjens. American Society of Hematology (ASH) 55th Annual Meeting December, 2013
23. Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy M L Davila, I. Riviere, X. Wang, S. Bartido, J. Stefanski, Q. He, O. Borquez-Ojeda, C. Taylor, T. Wasielewska, J. Qu, D.CG Bouhassira,Y J Bernal, S. Yoo, T. Purdon, E. Halton, H. Quintanilla, J H Park, K J. Curran, M. Sadelain, R. J Brentjens. American Society of Hematology (ASH) 55th Annual Meeting December, 2013
24. Interurban Clinical Club Bi-Annual Meeting November, 2013
25. 24th Annual Congress of the Hellenic Society of Haematology, November, 2013
26. Chemotherapy Foundation Symposium XXXI on Innovative Cancer Therapy for Tomorrow November, 2013
27. The Advent of Immunotherapy in Cancer Therapy, Memorial Hospital Alumni Society Symposium October, 2013
28. T cell Immunotherapy – Optimizing Trial Design Meeting September, 2013
29. International Society for Applied Biological Sciences Conference June, 2013
30. Cell Therapy and Interventional Immunology Conference June, 2013
31. Tumor Targeting Using CD19-Specific CAR (Chimeric Antigen Receptor) for B-Cell Lymphoma T. Tsukahara, K. Ohmine, R. Uchibori, H. Ido, M. Urabe, H. Mizukami, A. Kume, M. Nakamura, J. Mineno, K. Takesako, I. Riviere, M. Sadelain, R. Brentjens, K. Ozawa. American Society of Gene and Cell Therapy (ASGCT) 16th Annual Meeting May, 2013
32. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy Refractory Acute Leukemia R. Brentjens, M L Davila, I. Riviere, Jae Park, MD, X. Wang, S. Bartido, J. Stefanski, O. Borquez-Ojeda, Y. Bernal, M. Sadelain. American Society of Gene and Cell Therapy (ASGCT) 16th Annual Meeting May, 2013
33. American Society of Gene & Cell Therapy 16th Annual Meeting May, 2013
34. Herbert Irving Comprehensive Cancer Center (HICCC) Hematologic Malignancies Seminar April, 2013
35. American Association for Cancer Research Annual Meeting April, 2013
36. 4th Annual Conference on Cancer Biologics part of Cambridge Healthtech Institute’s 20th International Molecular Medicine Tri-Conference February, 2013
37. Rapid Molecular Remission and B Cell Aplasia Induced by CD19-Targeted T Cells in Adult Patients with B Cell Acute Lymphoblastic Leukemia (B-ALL) R. Brentjens, M. Davila, J. Park, I. Riviere, X. Wang, M. Frattini, M. Sadelain. Keystone Symposia 2013 : Cancer Immunology and Immunotherapy January, 2013
38. Constitutive Expression of CD40L by CAR-Modified Tumor Targeted T Cells Enhances Anti-Tumor Efficacy Both in Vitro and in Vivo K. J. Curran, B. Seinstra, Y. Nikhamin, R. Yeh, Y. Usachenko, R. J Brentjens.. American Society of Hematology (ASH)54th Annual Meeting December, 2012
39. Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19-28z CAR-Targeted T Cells M. L Davila, I. Riviere, X. Wang, J. H. Park, J. Stefanski, C. Taylor, Q. He, M. Olszewska, T. Wasielewska, O. Borquez-Ojeda, J. Qu, S. Bartido, J.G. Jurcic, D. Douer, M. G. Frattini, M. Sadelain, R. J Brentjens American Society of Hematology (ASH)54th Annual Meeting December, 2012
40. Micafungin versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy E. Halton, D. Chung, K. Xiao, H. Quintanilla, C. Baldwin, , P. Baird, E. Berman, R.J Brentjens, M. Heaney, J.G. Jurcic, N. Lamanna, T.L. Rosenblat, R.Kaplan, G. Papanicolaou, M.G. Frattini American Society of Hematology (ASH)54th Annual Meeting December, 2012
41. CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT K J. Curran, N. A. Kernan, X. Wang, C. Taylor, E. Doubrovina, S. Bartido, M. Sadelain, ,R. J. O'Reilly, R.J Brentjens, I. Rivière. American Society of Hematology (ASH)54th Annual Meeting December, 2012
42. Conditioning Intensity and T Cell Dose Determine Efficacy of CD19- Targeted T Cell-Mediated Tumor Eradication in an Immunocompetent Mouse Model of B-ALL M. L Davila, C. Kloss, R. J Brentjens, M.Sadelain. American Society of Hematology (ASH)54th Annual Meeting December, 2012
43. Highly Sensitive Bioluminescence in Vivo Imaging Enables Individualized Preclinical Treatment Trials on Patients ALL Tumor Cells Growing in Mice N. Terziyska, C. Castro Alves, M. Ogris, E. Wagner, R.J Brentjens, M.A. Horstmann, L. Quintanilla-Martinez, I. Jeremias American Society of Hematology (ASH)54th Annual Meeting December, 2012
44. Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia. J. R Gardner, S. Devlin, K. Knapp, F. Bauli, N. Lamanna, M.G. Frattini, R.J Brentjens, P. G. Maslak, J.G. Jurcic, M. Weiss, D.A. Scheinberg, M. Heaney. American Society of Hematology (ASH)54th Annual Meeting December, 2012
45. Impact of the Conditioning Chemotherapy on Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL J.H. Park, I. Rivière, X. Wang, J. Stefanski, Q. He, C. Taylor, M. Olszewska, T. Wasielewska, S. Bartido, M. L Davila, Y. Bernal, N. Lamanna, A. Noy, M. Sadelain, R. J Brentjens. American Society of Hematology (ASH) 54th Annual Meeting December, 2012
46. Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12 H.J. Pegram, J. Barker, S.Giralt, R. J Brentjens. American Society of Hematology (ASH)54th Annual Meeting December, 2012
47. American Society of Hematology 54th Annual Meeting December, 2012
48. Chemotherapy Foundation Symposium on Innovative Cancer Therapy for Tomorrow November, 2012
49. NYC Emerging Technologies Summit November, 2012
50. Japanese Society of Hematology 74th Annual Meeting October, 2012
51. 10th International Workshop on Non-Hodgkin Lymphoma September, 2012
52. International Society of Cell Therapy 18th Annual Meeting June, 2012
53. Developmental Therapeutics-Clinical Pharmacology and Immunotherapy Track, American Society of Clinical Oncology 48th Annual Meeting June, 2012
54. Evaluation of Anti-Tumor Effects Mediated by Engineered T Lymphocytes Expressing a CD19 Specific CAR for B Cell Lymphoma T. Tsukahara, K. Ohmine, R. Uchibori, H. Ido, M. Urabe, H. Mizukami, A. Kume, M. Nakamura, I. Rivère, M. Sadelain, R.J. Brentjens, K. Ozawa American Society of Gene and Cell Therapy (ASGCT) 15th Annual Meeting May, 2012
55. 16th Annual International Congress on Hematologic Malignancies February, 2012
56. In Vivo comparison of 3 Suicide Gene-Prodrug Combinations in a Mouse Graft-Versus-Host-Disease Model J. H. Park, R. Yeh, I. Riviere, M. Sadelain, R. Brentjens. American Society of Hematology (ASH) 53rd Annual Meeting December, 2011
57. Enhanced Antitumor Efficacy of MUC-16 Targeted T Cells Further Modified to Constitutively Express the IL-12 Cytokine in a Syngeneic Model of Ovarian Cancer. A. A Chekmasova, S. Sandadi, D. R Spriggs, R. J Brentjens American Society of Hematology (ASH) 53rd Annual Meeting December, 2011
58. Tumor Specific T Cells Modified to Secrete IL-12 Eradicate Systemic Tumors in the Absence of Prior Toxic Chemotherapy Conditioning Regimens. H. J. Pegram, J. Lee, E. Hayman, G. H Imperato, T. J. Tedder, R. J Brentjens. American Society of Hematology (ASH) 53rd Annual Meeting December, 2011
59. Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History J R Gardner, K. Knapp, M.G. Frattini, N. Lamanna, R. Brentjens, J.G Jurcic, P G. Maslak, E. Berman, M..Weiss, D. A. Scheinberg, M. Heaney. American Society of Hematology (ASH) 53rd Annual Meeting December, 2011
60. 2nd Annual Asian Cellular Therapy Organization Meeting October, 2011
61. Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells R. J. Brentjens, I. Riviere, J. Park, M. Davilla, X. Wang, R. Yeh, N. Lamanna, M. G. Frattini, M. Sadelain American Society of Clinical Oncology (ASCO) 47th Annual Meeting June, 2011
62. Preston Robert Tisch Brain Tumor Center Seminar June, 2011
63. Anti-Tumor Activity of Engineered T Lymphocytes Expressing an Anti-CD19 CAR for B Cell Lymphoma T. Tsukahara, K. Ohmine, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, I. Rivère, M. Sadelain, R.J. Brentjens, K. Ozawa American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting May, 2011
64. Validation of Donor Derived Virus Specific T-Lymphocytes Genetically Modified To Target the CD19 Antigen for the Treatment of Relapsed Leukemia K. Curran, C. Taylor, E. Doubrovina, X. Wang, R. O’Reilly, M. Sadelain, N. Kernan, R.J. Brentjens, I. Rivère. American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting May, 2011
65. American Society of Gene and Cell Therapy 14th Annual Meeting May, 2011
66. Expansion and Anti-Tumor Efficacy of CD19 Targeted Cord Blood T Cells H.J. Pegram, V. La Russa, R.J. Brentjens American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting May, 2011
67. Effective Eradication of Established Ovarian Murine Tumors with MUC16 Targeted T Cells Expressing IL-12 Gene A.A. Chekmasova, S. Sandadi, Y. Nikhamin, D.R. Spriggs, R.J. Brentjens American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting May, 2011
68. Cold Spring Harbor Laboratory Stem Cell Engineering and Cell-Based Therapies Meeting April, 2011
69. Clinical Trials and Translational Research Advisory Committee 13th Meeting, National Cancer Institute March, 2011
70. CD19 Targeted Cord Blood Derived T Cells for Cancer Immunotherapy H. J. Pegram, V.LaRussa, R. Brentjens 52nd ASH Annual Meeting December, 2010
71. In Vitro analysis of Suicide Gene Expression and Function of 3 Suicide Gene-Prodrug Combinations in Human T Lymphocytes Further Modified to Express the CD19 Targeted 19-28z Chimeric Antigen Receptor J. H. Park, R. Yeh, I. Rivière, M. Sadelain, and R. J. Brentjens. 52nd ASH Annual Meeting December, 2010
72. B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen M.L. Davila, C.Taylor, X. Wang, J. Stefanski, M. Olszewska, S. Bartido, M. Frattini, M. Sadelain, I. Rivière, R.J. Brentjens 52nd ASH Annual Meeting December, 2010
73. Characteristic Proinflammatory Serum Cytokine Profiles in Patients with B-Cell Chronic Lymphocytic Leukemia J.J. Harding, R. Yeh, Y. Nikhamin, M. Frattini, N. Lamanna, J. G Jurcic, M. Heaney, R.Brentjens. 52nd ASH Annual Meeting December, 2010
74. Adoptive Therapy with Human CD19 (hCD19)-Targeted T Cells Further Modified to Express IL-12 Overcome the Need for Prior Lymphodepletion to Eradicate Established hCD19+ Tumors and Induce B Cell Aplasias In Immune Competent hCD19+Transgenic Mice E. Hayman, J. Lee, H. J. Pegram, R. Brentjens. 52nd ASH Annual Meeting December, 2010
75. Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen Eradicates Systemic Lymphoma In Mice K.J. Curran, C. Taylor, E. Doubrovina, X. Wang, R. J. O'Reilly, M. Sadelain, N. A. Kernan, R.J. Brentjens, and I. Rivière. 52nd ASH Annual Meeting December, 2010
76. ATTACK, 3rd Cellular Therapy of Cancer Symposium September, 2010
77. Department of Microbiology and Immunology Seminar August, 2010
78. National Institutes of Health, Office of Biotechnology Activities Symposia June, 2010
79. In vitro analysis of suicide gene expression and function in human T lymphocytes transduced to express a tumor-targeted chimeric antigen receptor J. H. Park, R. Yeh, I. Rivère, M. Sadelain and R. J. Brentjens American Society of Clinical Oncology (ASCO) 46th Annual Meeting June, 2010
80. In vitro analysis of suicide gene expression and function in human T lymphocytes transduced to express a tumor-targeted chimeric antigen receptor J. H. Park, R. Yeh, I. Rivère, M. Sadelain and R. J. Brentjens ASGCT 2010 meeting May, 2010
81. Genetically mediated constitutive expression of CD40L by T cells will induce enhanced immunogenicity of B cell malignancies KJ Curran, R Yeh, B Seinstra, Y Nikhamin, Y Usachenko, RJ Brentjens. ASGCT 2010 meeting May, 2010
82. Marked regression of adenopathy following infusion of autologous T cells genetically targeted to the CD19 antigen in a patient with bulky CLL. RJ Brentjens, I Riviere, M Frattini, X Wang, C Taylor, M Olszewska, O Borquez-Ojeda, S Bartido, J Stefanski, R Yeh, M Sadelain ASGCT 2010 meeting May, 2010
83. Adoptive transfer of T cells genetically targeted to the MUC16 antigen eradicates established peritoneal ovarian tumors in SCID-Beige mice AA Chekmasova, TD Rao, DR Spriggs, RJ Brentjens. ASGCT 2010 meeting May, 2010
84. Cold Spring Harbor Laboratories Symposia: In Vivo Barriers to Gene Delivery, Cold Spring Harbor, NY November, 2009
85. Immunology Research Conference, City University of New York, Hunter College, New York, NY November, 2009
86. Critical Frontiers Between Immunity and Gene Therapy, International symposium, Pamplona, Spain October, 2009
87. American Society of Gene Therapy Annual Meeting, Outstanding New Investigator Symposium May, 2009
88. ATTACK, 2nd Cellular Therapy of Cancer Symposium, Milan, Italy March, 2009
89. Tumor Targeted T cells modified to express IL-12 overcome inhibition mediated by the hostile tumor microenvironment J Lee, M Sadelain, RJ Brentjens Keystone symposia 2009, Mobilizing Cellular Immunity for Cancer Therapy January, 2009
90. Immunology Seminar, Washington University October, 2008
91. Center for Cell Engineering Inaugural Retreat, Memorial Sloan-Kettering Cancer Center, January, 2008
92. Takara Biotechnology Inc Research Seminar. Kyoto, Japan September, 2007
93. The 4th Nikko International Symposium, Jichi Medical University September, 2007
94. Immunology Seminar, University of Miami Sylvester Comprehensive Cancer Center March, 2007
95. Functional Characterization of Genetically Modified Tumor-Targeting Regulatory T Cells J Lee, Y Nikhamin, R Brentjens. World Immune Regulation Meeting 2007 January, 2007
96. CD19-targeted CLL patient T cells expanded with beads eradicate systemic B cell tumors in vivo Riviere, D Hollyman, J Stefanski, M Przybylowski, V Capacio, O Borquez-Ojeda, S Bartido, J Hosey, M Sadelain, R Brentjens Keystone Symposia 2007, Potent New Anti-tumor Therapies. Poster #305 January, 2007
97. A phase I trial for the treatment of purine analogue refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19 R. Brentjens, I. Rieviere, D. Hollyman, J. Stefanski, M. Przybylowski, S. Bartido, O. Borquez-Ojeda, C. Taylor, J.Hosey, M. Heaney, M. Weiss, M. Sadelain 12th International Workshop on CLL. January, 2007
98. Immunology Seminar, Roswell Park Cancer Institute November, 2006
99. Microbiology/Immunology Seminar, SUNY at Buffalo November, 2006
100. Salzburg Medical Seminars - Oncology 2006. September, 2006
101. Cancer-Immunotherapy: Lymphocyte Targets for Gene Therapy American Society of Gene Therapy 9th Annual Meeting June, 2006
102. Experimental Therapeutics Center Retreat, Memorial Sloan-Kettering Cancer Center May, 2006
103. Hematology/Oncology Grand Rounds New York Presbyterian Hospital, Weill Medical College February, 2006
104. Translational Research Seminar Series, Memorial Sloan-Kettering Cancer Center June, 2004
105. Salzburg Medical Seminars Oncology 2003 November, 2003
106. Genetic Modification of Autologous Peripheral Blood T Cells: A Feasible Immuno-Therapeutic Approach for the Treatment of Chronic Lymphocytic Leukemia (CLL) R. Brentjens, M. Weiss, M. Sadelain 10th International Workshop on CLL January, 2003



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
13th International Congress on Targeted Anticancer Therapies 13th International Congress on Targeted Anticancer Therapies March, 2015
CAR - based cellular therapies SciBX Summit on Innovation in Drug Discovery and Development 2013 October, 2013
8th ISABS Conference on Forensic, Anthropologic and Medical Genetics 8th ISABS Conference on Forensic, Anthropologic and Medical Genetics June, 2013
Genetically Engineered Immune Cells in Immunotherapy Chairperson: Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA AACR Annual Meetings April, 2013

Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.